FDA’s ODAC Unanimously Recommends Biosimilar Versions of Bevacizumab and Trastuzumab

July 14, 2017 – On July 13, the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of biosimilar versions of bevacizumab and trastuzumab. In the morning session, ODAC members voted 17-0 in favor of approving Amgen’s bevacizumab biosimilar candidate, ABP 215 … (leggi tutto)